Eli Lilly and Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Eli Lilly and.

Eli Lilly and will be holding an earnings conference call on Tuesday, October 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Monday, August, 2nd. The company reported $1.87 EPS for the quarter, missing analysts' consensus estimates of $1.89 by $0.02. The business earned $6.74 billion during the quarter, compared to analyst estimates of $6.59 billion. Eli Lilly and had a net margin of 22.71% and a trailing twelve-month return on equity of 119.12%. The firm's revenue was up 22.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.89 earnings per share.
View Eli Lilly and's earnings history.

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LLY shares have increased by 64.4% and is now trading at $230.17.
View which stocks have been most impacted by COVID-19.

Eli Lilly and declared a quarterly dividend on Tuesday, June 29th. Shareholders of record on Friday, August 13th will be given a dividend of $0.85 per share on Friday, September 10th. This represents a $3.40 annualized dividend and a yield of 1.48%. The ex-dividend date of this dividend is Thursday, August 12th.
View Eli Lilly and's dividend history.

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.47%. Eli Lilly and does not yet have a strong track record of dividend growth. The dividend payout ratio of Eli Lilly and is 42.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.05% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

Eli Lilly and announced that its Board of Directors has authorized a share buyback program on Monday, May 3rd 2021, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Eli Lilly and issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share (EPS) guidance of $7.800-$8.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.900. The company issued revenue guidance of $26.80 billion-$27.40 billion, compared to the consensus revenue estimate of $27.22 billion.

16 Wall Street analysts have issued twelve-month target prices for Eli Lilly and's shares. Their forecasts range from $144.00 to $300.00. On average, they expect Eli Lilly and's share price to reach $250.81 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Omeros (OMER).
View all of LLY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by many different institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.41%), Vanguard Group Inc. (7.19%), BlackRock Inc. (6.35%), PNC Financial Services Group Inc. (5.44%), Primecap Management Co. CA (3.54%) and State Street Corp (3.43%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

LLY stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Lilly Endowment Inc., Swiss National Bank, Alphinity Investment Management Pty Ltd, Bridge Creek Capital Management LLC, Massachusetts Financial Services Co. MA, Capital International Investors, and Parallax Volatility Advisers L.P.. Company insiders that have sold Eli Lilly and company stock in the last year include Donald A Zakrowski, and Lilly Endowment Inc.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

LLY stock was bought by a variety of institutional investors in the last quarter, including Amundi, Jennison Associates LLC, BlackRock Inc., AMF Pensionsforsakring AB, Macquarie Group Ltd., Mn Services Vermogensbeheer B.V., Price T Rowe Associates Inc. MD, and Geode Capital Management LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $230.17.

Eli Lilly and has a market capitalization of $220.74 billion and generates $24.54 billion in revenue each year. The company earns $6.19 billion in net income (profit) each year or $7.93 on an earnings per share basis.

Eli Lilly and employs 35,000 workers across the globe.

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

Eli Lilly and was founded in 1876.

The official website for Eli Lilly and is www.lilly.com.

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at (317) 276-2000 or via email at [email protected].